Spleen tyrosine kinase (Syk) signaling is central to phagocytosis-based, antibody-mediated platelet destruction in adults with immune thrombocytopenia (ITP). Fostamatinib, an oral Syk inhibitor, produced sustained on-treatment responses in a phase 2 ITP study. In two parallel, phase 3, multicenter, randomized, double-blind, placebo-controlled trials (FIT1 and FIT2), patients with persistent/chronic ITP were randomized 2:1 to fostamatinib (n 5 101) or placebo (n 5 49) at 100 mg BID for 24 weeks with a dose increase in nonresponders to 150 mg BID after 4 weeks. The primary endpoint was stable response (platelets 50 000/lL at 4 of 6 biweekly visits, weeks 14-24, without rescue therapy). Baseline median platelet count was 16 000/lL; median duration of ITP was 8.5 years. Stable responses occurred in 18% of patients on fostamatinib vs. 2% on placebo (P 5 .0003). Overall responses (defined retrospectively as 1 platelet count 50 000/lL within the first 12 weeks on treatment) occurred in 43% of patients on fostamatinib vs. 14% on placebo (P 5 .0006). Median time to response was 15 days (on 100 mg bid), and 83% responded within 8 weeks. The most common adverse events were diarrhea (31% on fostamatinib vs. 15% on placebo), hypertension (28% vs. 13%), nausea (19% vs. 8%), dizziness (11% vs. 8%), and ALT increase (11% vs. 0%). Most events were mild or moderate and resolved spontaneously or with medical management (antihypertensive, anti-motility agents). Fostamatinib produced clinically-meaningful responses in ITP patients including those who failed splenectomy, thrombopoietic agents, and/or rituximab. Fostamatinib is a novel ITP treatment option that targets an important mechanism of ITP pathogenesis.
comparative, randomized, controlled studies exist to facilitate treatment choice. 9, 10 Splenectomy is the only potentially curative approach, which is effective in a majority of patients initially, but some patients subsequently relapse. This surgical option is declining in use due to the availability of noninvasive options. 11 Medical therapies, such as rituximab, thrombopoietin receptor agonists, and immunosuppressive agents, have been effective in many patients and are chosen according to physician and patient preference. Some patients do not respond, or respond but relapse, when treated with second line treatments and develop persistent and then chronic disease. Those who do not improve often cycle endlessly through the various treatment options. Despite the multiple agents available, there is an unmet medical need for patients with ITP. 6, 7, 12, 13 Fostamatinib, an orally bioavailable, small molecule spleen tyrosine kinase (Syk) inhibitor, was approved in April 2018 by the US Food and Drug Administration (FDA) for the treatment of chronic ITP in adults who have had an insufficient response to a prior therapy. All activating Fc receptors signal via Syk, which has roles in cellular proliferation, differentiation, survival, immune regulation, and cytoskeletal rearrangements during phagocytosis. [14] [15] [16] Syk is also linked to signaling of the B cell receptor and has been implicated in autoantibody production. 17 Inhibition of Syk using fostamatinib reduced platelet destruction in a mouse model of passive ITP, underscoring the role of Syk in phagocytosis of antibody-coated platelets. 18 Clinical results with fostamatinib were first reported in patients with chronic ITP in a single center study in 2009. Of 16 patients, 8 (50%) achieved long-term responses, with manageable adverse events (AEs). 18 Fostamatinib was also extensively studied in rheumatoid arthritis, demonstrating efficacy and establishing a safety profile in a total of more than 3000 patients. [19] [20] [21] [22] [23] [24] [25] This report describes two identical, parallel, multicenter, randomized, double-blind, placebo-controlled, phase 3 studies comparing fostamatinib to placebo in 150 adults with persistent and primarily chronic ITP of very longlasting duration, who had failed a number of prior treatments. to balance patients with prior splenectomy and degree of thrombocytopenia (platelet count < or 15 000/lL). Both studies were approved by independent ethics committees at participating centers, performed in accordance with the Declaration of Helsinki, and designed in accordance with FDA Guidance. All patients provided written informed consent. 
| M E TH ODS

| Study design
| Patients
| Treatments
Prior to randomization, patients had a washout period, during which therapeutic agents, other than those allowed as concomitant ITP therapies, were discontinued for up to 8 weeks. Patients were allowed to continue one concomitant ITP medication (corticosteroids at <20 mg prednisone equivalent per day, azathioprine, or danazol) throughout the study without any changes if they were on a stable dose for 14 days prior to baseline. Rescue therapies (e.g., increased dosing of concomitant ITP therapy, IVIg, IV anti-D, steroids, platelet transfusion)
were allowed.
Fostamatinib was administered at 100 mg BID and could be increased to 150 mg BID after 4 weeks or later, depending on platelet count. Doses could be reduced to fostamatinib 100 or 150 mg once daily if a dose-limiting AE occurred. The need for dose modifications was determined during biweekly visits.
Patients who completed the 24-week study treatment could enroll in the long-term, open-label extension study (Study 049; NCT02077192). Nonresponders who were treated for 12 weeks and received 150 mg BID of study drug for 4 weeks could also enter the extension study.
| Efficacy and safety assessments
The primary efficacy endpoint was a stable response by week 24
(defined as platelet counts 50 000/lL on at least 4 of the 6 clinic visits occurring every 2 weeks during weeks 14-24 inclusive); patients receiving rescue medication after week 10 were considered nonresponders. A secondary efficacy platelet endpoint was measured in patients with baseline platelet count <15 000/lL: achievement of platelet counts 30 000/lL and at least 20 000/lL above baseline at weeks 12 and 24. Bleeding events were tabulated both for efficacy and safety. Data from FIT1and FIT2 were analyzed separately and pooled. Safety assessments and platelet counts were conducted during biweekly clinic visits 13 times over the 24-week treatment period.
| Post hoc assessments
Post hoc assessments included overall response, which was defined as a platelet count 50 000/lL within the first 12 weeks without rescue medication in the preceding 4 weeks; the initial 12 weeks were selected since most nonresponding patients from both arms discontin- The primary efficacy endpoint was analyzed using the prespecified imputation method of last observation carried forward (LOCF). A sensitivity analysis was conducted such that missing data were imputed as <50 000/mL (nonresponse). One patient in FIT2 randomized to fostamatinib had 5 consecutive study counts > 50 000/lL culminating at week 16; the patient then moved and thus had to leave the study. This patient was considered a stable responder in the prespecified analysis using LOCF and was a nonresponder in the sensitivity analysis.
Efficacy endpoints were summarized using counts and percentages, and 95% exact (Clopper-Pearson) confidence intervals (CI Patient characteristics at baseline were well-balanced between the placebo and fostamatinib groups, including age (median 53 vs 54 years), sex (61% vs 60% female), and number of prior treatments (median 3
for both groups, range 1-13) except that FIT2 placebo patients had higher median platelet counts (Table 1) . Patient characteristics were similar between FIT1 and FIT2 except that FIT1 and FIT2 patients were from different geographic areas. Compared to FIT1 patients, FIT2
patients had a longer median duration of ITP, lower rates of prior splenectomy, IVIg/anti-D, TPO-RA, and rituximab use, and higher rates of prior cyclophosphamide, vinca alkaloids, and danazol ( Table 1 ).
The patient characteristics illustrate a difficult-to-treat population with long-standing ITP (median of 8.5 years and approximately 75%
had had ITP for 3 years), many attempts at prior therapy for ITP (median of 3 unique prior therapies and as many as 13), and an average platelet count at baseline that is typically associated with bleeding episodes (more than half were below 15 000/lL).
The 24 weeks of treatment were completed by more patients on fostamatinib compared with patients on placebo (Supporting Information Figure S1 ). Rates of and reasons for study discontinuation were similar between studies. The majority of nonresponders on fostamatinib and most patients on placebo discontinued study treatment at Week 12 to enter the open-label, long-term extension study: 88% of patients in FIT1 and 79% in FIT2 on placebo vs. 55% in FIT1 and 66%
in FIT2 on fostamatinib.
| Efficacy
More patients on fostamatinib achieved the primary endpoint of stable response (platelets > 50 000/mL without rescue at 4 of 6 visits, weeks On fostamatinib, 43 of 101 (43%) patients achieved an overall response, defined as at least 1 platelet count > 50 000/lL within the first 12 weeks (including stable responders), compared with 7 of 49 (14%) on placebo (P 5 .0006; Figure 1A ). Overall responses occurred in 37% of patients on fostamatinib vs. 8% on placebo in FIT1 (P 5 .007), and in 48% on fostamatinib vs. 21% on placebo in FIT2 (P 5 .025).
Among patients with more severe thrombocytopenia at baseline (platelet counts <15 000/mL), an increase of 20 000/mL to a platelet count of 30 000/mL at weeks 12 and 24 was achieved by 10/47 (21%) and 7/47 (15%) on fostamatinib and by 1/21 (5%) and 0/21 (0%) on placebo in the pooled analysis.
The median duration of ITP at study entry was 8.7 years for stable responders, 6.5 years for overall responders and 10.3 years for nonresponders. The 8 patients between both studies with persistent ITP had 6 overall responses, 1 of which was a stable response. Overall responses were seen across a wide range of ITP durations, including those with a duration of <3 years (52%), 3 to <8 years (48%) and 8 years (36%); however, there was no correlation of response with duration of ITP at study entry.
Median platelet counts are shown in Figure 1B . Among stable and overall responders, median platelet counts increased by week 2 on fostamatinib and remained above 50 000/lL at nearly all time points (Figures 2A,B) . By contrast, the median platelet counts for nonresponders and placebo patients remained well below 50 000/lL for the duration of the study with one exception. The median platelet count spiked at Patients were allowed to continue one concomitant ITP medication throughout the study without any changes if they were on a stable dose for 14 days prior to baseline, and 70 (46%) patients did so. Of those, 59 (39.3%) were on corticosteroids, 5 (3.3%) were on immunoglobulins, 7 (4.7%) were on azathioprine, and 2 (1.3%) were on danazol.
Only 2 patients with a stable platelet response were on a concomitant medication, and both were on steroids (for 62 days and 14 years prior In contrast, nonresponders received rescue medication throughout the study period (weeks 0-24).
| Safety
In FIT1 and FIT2, 83% and 75% of patients experienced AEs in the fostamatinib and placebo groups, respectively. The most commonly reported AEs were diarrhea, nausea, hypertension, dizziness, and ALT and/or AST increases ( leading to fostamatinib dose reductions were diarrhea and hypertension. The most common AEs (2%) leading to fostamatinib dose interruptions were ALT increased, diarrhea, and influenza-like illness.
AEs known to occur with fostamatinib and assessed as groups of relevant preferred terms included: neutropenia (7% on fostamatinib vs 0% on placebo), gastrointestinal events (41% vs 21%), transaminase elevation to > 3 times normal (9% vs 0%; no drug-induced liver injury in either group), and hypertension-type events (28% vs 13%).
SAEs were experienced by 13% of patients on fostamatinib and 21% on placebo. Only 3 types of SAEs were reported in more than 1 patient in either treatment group: epistaxis (2% fostamatinib vs. 2% placebo), thrombocytopenia (1% vs. 4%), and menorrhagia (0% vs. 4%).
SAEs were considered related to study drug in 4% of patients on fostamatinib and 2% on placebo. There were 2 fatalities. In FIT1, a patient on placebo died of probable sepsis 19 days after discontinuing the study due to epistaxis. In FIT2, plasma cell myeloma led to withdrawal of fostamatinib on Day 19 and death 71 days later. There were no thromboembolic events.
| D ISC USSION
FIT1 and FIT2 were identical, parallel, double-blind, randomized phase 3 trials evaluating a Syk inhibitor, fostamatinib, vs. placebo in a total of 150 adult patients with persistent or (predominantly) chronic ITP. The studies were designed in accordance with FDA guidance, using standard methods to avoid bias, and the efficacy endpoints were based on an objective laboratory assessment of platelet count. These phase 3 studies were the first to evaluate second-or third-line treatment for ITP in the current era of widespread use of TPO-RA and rituximab.
FIT1 and FIT2 were relatively large studies, with 75 patients each, of a "rare" disease (ITP). These 2 studies included patients with a very long duration of disease and a median of 3 prior treatments. In the pooled analysis, stable platelet response, achieved by 18 of 101 patients on fostamatinib, and overall platelet response, achieved by 43 of 101 patients on fostamatinib, were both significantly higher in fostamatinibtreated patients than in placebo-treated patients. Furthermore, the overall (including the stable) responses were associated with reductions in both bleeding and use of rescue medication. These findings demonstrate that almost half of patients had overall platelet responses to fostamatinib, despite some not reaching the primary endpoint, and that these responses were clinically meaningful, based on decreased bleeding events and a decreased need for rescue medication and not just numerical values. The efficacy findings were robust since the responses were similar between the two studies and consistent with the phase 2 ITP study results. These studies led to the FDA approval of fostamatinib for the treatment of chronic ITP in adults who have had an insufficient response to a prior therapy.
The primary endpoint and inclusion criteria used in this study were more stringent than those used in certain studies of avatrombopag and eltrombopag, in which eligibility platelet counts were assessed on a single day. [28] [29] [30] [31] The primary endpoint in FIT1 and FIT2 required patients to achieve high platelet counts (>50 000/lL) at multiple timepoints (4 of 6 over weeks [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , which is similar (although not identical) to the pivotal romiplostim studies. In the latter study, the durable response endpoint was met by 38% of splenectomized patients, comparable to what was seen here. 32 To provide a more complete description of meaningful responses elicited by fostamatinib, an additional post hoc efficacy endpoint of overall platelet response (>50 000/lL) within the first 12 weeks of the study was assessed. Overall responders had elevated median platelet counts corresponding to more consistently increased platelet counts rather than just one increased count, supporting the appropriateness of this post hoc endpoint.
Most patients (75%) in the study had ITP lasting more than 3 years (median 8.5 years) at study entry. Consistent with the long duration of disease, this was a population with at least 2-3 prior therapies in almost all cases. These exposures included frequent prior use of TPO-RA-based therapy (48%), rituximab (34%), and splenectomy (35%).
More than half the patients had baseline platelet counts below rituximab. 33 Further studies are needed to explore clinical and laboratory factors predictive of fostamatinib sensitivity.
Dose selection for FIT1 and FIT2 was based on results of the phase 2 ITP study where doses up to 175 mg BID were associated with better response rates but apparently more toxicity. Therefore, the phase 3 trials were designed to start patients at a dose of fostamatinib 100 mg BID, with a dose increase to 150 mg BID permitted at week 4.
Almost all stable responders up-titrated to 150 mg BID to achieve and/ or sustain their responses to fostamatinib. The degree of Syk blockade at these doses was not investigated in this study. The likelihood that higher doses of fostamatinib would yield higher response rates is uncertain, but there would likely be more adverse events.
The safety profile of fostamatinib was consistent with prior experience in the phase 2 ITP study and the large rheumatoid arthritis studies;
no new AEs of note were seen. [18] [19] [20] [21] [22] [23] [24] The most commonly reported AEs included diarrhea, hypertension, nausea, and transaminase elevation. An increased rate of hypertension has been previously reported with fostamatinib in the Phase 2 ITP study and studies of rheumatoid arthritis 20, 21 and appears to be due to off-target effects on VEGFR2. [34] [35] [36] Most AEs were mild or moderate. Gastrointestinal disorders and hypertension were medically managed as needed with antihypertensive and antimotility agents. 37 The number of overall responders discontinuing fostamatinib was small (3 of 43) and did not include any stable responders;
however, other patients required dose interruption or dose reduction because of adverse events and also medication to manage their AEs.
Limitations to these paired studies included the very long duration of disease in enrolled patients, which exceeds that of other published ITP studies. Furthermore, the prior use of many other well-established treatments, e.g., immunosuppressives, rituximab, splenectomy, and especially TPO-RA agents, likely also biased the study against a good response to fostamatinib. Other studies have shown that responses to rituximab and anti-CD40 ligand were lower in ITP patients with very long disease duration. 38, 39 Other effective therapies for ITP are thought to inhibit platelet destruction, e.g., IVIG, IV anti-D, vincristine, and danazol. IVIg and IV anti-D both inhibit platelet destruction but very likely impact different FcR receptors, which may explain their apparently additive effects. 39, 40 There are multiple distinct pathways involved in immune-mediated platelet destruction, and treatments interfering with platelet destruction may have nonoverlapping effects. 39 This could explain responses to fostamatinib in patients who were unresponsive to other therapies.
In summary, fostamatinib targets the Syk-mediated pathway of platelet-destruction, producing a stable response (>50 000/lL at 4 of 6 counts during weeks 14-24) in 18% of patients on fostamatinib compared with 2% on placebo and an overall response in 43% on fostamatinib compared to 14% in placebo. Fostamatinib has a unique mechanism of action, dissimilar to other approved ITP therapies, and produced responses in patients who had relapsed or not responded to TPO-RA agents, rituximab, and/or splenectomy. The ongoing openlabel extension study will broaden the understanding of the long-term clinical efficacy and safety of fostamatinib in adults with ITP. Future studies will investigate whether higher response rates will be seen when fostamatinib is given earlier in the course of ITP, further study the mechanism of Syk inhibition, and explore which patients are most likely to respond to treatment.
